Atlas Trials

Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence

Clinical trial NCT01079988 · COMPLETED

Trial details

NCT number
NCT01079988
Sponsor
Merck KGaA, Darmstadt, Germany
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Psoriasis
Start date
2004-02-01
Primary completion
2004-12-01
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.